Toll Free: 1-888-928-9744

Contact Dermatitis - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Contact Dermatitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Contact Dermatitis - Pipeline Review, H2 2016, provides an overview of the Contact Dermatitis (Dermatology) pipeline landscape.

Contact dermatitis is a type of skin inflammation that occurs when substances touching skin cause irritation or an allergic reaction. Signs and symptoms of contact dermatitis include red rash or bumps, dry, cracked, red patches, which may resemble a burn and pain or tenderness. There are two types of contact dermatitis; irritant and allergic. Irritant dermatitis, the most common type, is caused by contact with acids, alkaline materials such as soaps and detergents, fabric softeners, solvents, or other chemicals. The reaction usually looks like a burn. Allergic contact dermatitis is an itchy skin condition caused by an allergic reaction to allergen. Treatment includes oral corticosteroids and antihistamines to relieve intense itching. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Contact Dermatitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Contact Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Contact Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 9 respectively for Contact Dermatitis.

Contact Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Contact Dermatitis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Contact Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Contact Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Contact Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Contact Dermatitis (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Contact Dermatitis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Contact Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Contact Dermatitis Overview 7 Therapeutics Development 8 Pipeline Products for Contact Dermatitis - Overview 8 Contact Dermatitis - Therapeutics under Development by Companies 9 Contact Dermatitis - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Contact Dermatitis - Products under Development by Companies 14 Contact Dermatitis - Companies Involved in Therapeutics Development 15 Aldeyra Therapeutics Inc 15 Anacor Pharmaceuticals, Inc. 16 AskAt Inc. 17 Brickell Biotech, Inc. 18 Dr. August Wolff GmbH & Co. KG Arzneimittle 19 Edesa Biotech Inc 20 Hapten Sciences, Inc. 21 ILiAD Biotechnologies, LLC 22 LegoChem Biosciences, Inc 23 Marinomed Biotechnologie GmbH 24 Novartis AG 25 Signum Dermalogix, Inc 26 Sucampo Pharmaceuticals, Inc. 27 Contact Dermatitis - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 AAT-008 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 ADX-102 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 AN-3485 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 BBI-2000 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 beta-escin - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 EB-01 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 HPT-721 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 LCB-030110 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 pertussis [strain BPZE1] vaccine - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 RTU-1096 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 secukinumab - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 SIG-1322 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 WOL-071007 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Contact Dermatitis - Dormant Projects 65 Contact Dermatitis - Discontinued Products 66 Contact Dermatitis - Product Development Milestones 67 Featured News & Press Releases 67 Nov 19, 2015: Hapten Sciences to Begin Clinical Trials for Novel Poison Ivy Vaccine 67 Appendix 68 Methodology 68 Coverage 68 Secondary Research 68 Primary Research 68 Expert Panel Validation 68 Contact Us 68 Disclaimer 69
List of Tables
Number of Products under Development for Contact Dermatitis, H2 2016 8 Number of Products under Development by Companies, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Contact Dermatitis - Pipeline by Aldeyra Therapeutics Inc, H2 2016 15 Contact Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016 16 Contact Dermatitis - Pipeline by AskAt Inc., H2 2016 17 Contact Dermatitis - Pipeline by Brickell Biotech, Inc., H2 2016 18 Contact Dermatitis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H2 2016 19 Contact Dermatitis - Pipeline by Edesa Biotech Inc, H2 2016 20 Contact Dermatitis - Pipeline by Hapten Sciences, Inc., H2 2016 21 Contact Dermatitis - Pipeline by ILiAD Biotechnologies, LLC, H2 2016 22 Contact Dermatitis - Pipeline by LegoChem Biosciences, Inc, H2 2016 23 Contact Dermatitis - Pipeline by Marinomed Biotechnologie GmbH, H2 2016 24 Contact Dermatitis - Pipeline by Novartis AG, H2 2016 25 Contact Dermatitis - Pipeline by Signum Dermalogix, Inc, H2 2016 26 Contact Dermatitis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 27 Assessment by Monotherapy Products, H2 2016 28 Number of Products by Stage and Target, H2 2016 30 Number of Products by Stage and Mechanism of Action, H2 2016 32 Number of Products by Stage and Route of Administration, H2 2016 34 Number of Products by Stage and Molecule Type, H2 2016 36 Contact Dermatitis - Dormant Projects, H2 2016 65 Contact Dermatitis - Discontinued Products, H2 2016 66



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify